Q3FY26 RESULTS UPDATE Dr. Reddy's 1 | September 2025 | Investor Presentation | As per consolidated financial statements under IFRS Safe Harbor Statement Dr. Reddy's •·· ~;• 21 JANUARY 2026 This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statemen ...

Company Overview - Immutep Limited (NASDAQ:IMMP) is a biotechnology company focused on developing therapies for cancer and autoimmune diseases [2]. Recent Developments - The company recently entered into an agreement with Dr. Reddy's Laboratories Ltd.'s subsidiary to develop and commercialize its Eftilagimod Alfa drug outside of North America, Europe, Japan, and Greater China [2]. - Immutep will retain manufacturing rights for Eftilagimod Alfa and will receive a $20 million upfront payment from Dr. Reddy [2]. Clinical Trials and Efficacy - Positive results from phase one and phase two studies were reported, with the phase two study showing efficacy in patients with soft tissue sarcoma when combined with radiotherapy and Merck's Keytruda [4]. - The phase one study demonstrated an 81% survival rate over 24 months for metastatic non-squamous non-small cell lung cancer when Eftilagimod Alfa was used as a first-line treatment in combination with Keytruda and chemotherapy [4].